Inflectra becomes first FDA-approved biosimilar for inflammatory diseases

A biosimilar version of the anti–tumor necrosis factor–alpha agent Remicade has been approved by the Food and Drug Administration, making it the first biosimilar drug approved by the agency for...
Source: Rheumatology News - Category: Rheumatology Source Type: research